Disease · MONDO_0008054

juvenile dermatomyositis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. juvenile dermatomyositis. Diseases, record MONDO_0008054. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008054

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: juvenile dermatomyositis; Open Targets
Open Targets ID: MONDO_0008054; Open Targets
Other names: Childhood Type Dermatomyositides, Childhood Type Dermatomyositis, Dermatomyositides, Childhood Type, Dermatomyositis, Childhood Type, childhood dermatomyositis, childhood type dermatomyositis (disorder), inflammation of myoseptum, juvenile DM, myoseptum inflammation, myoseptumitis; Open Targets
Disease Ontology: DOID:14203; Disease Ontology
MeSH: C000598745; MeSH
NCI Thesaurus: C27576; NCI Thesaurus
Orphanet: ORPHA:93672; Orphanet
Highest stage of its drugs: Approval, for 1 of its 15 drugs, from ClinicalTrials.gov; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BARICITINIB	CHEMBL2105759	Small molecule	Approval	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DEUCRAVACITINIB	CHEMBL4435170	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
PPIA	Peptidyl-prolyl cis-trans isomerase A	1	Cyclophilin A modulator	Phase 3	https://conductscience.org/library/genes/5478	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 2/3	https://conductscience.org/library/genes/7124	Drugs and targets
TYK2	Non-receptor tyrosine-protein kinase TYK2	1	Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05000216	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Phase 2	258	2025-08-22	Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)	ELASOMERAN, TOZINAMERAN	Its record names the disease	ClinicalTrials.gov
NCT00323960	Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis	Phase 3	139	2021-03-16	Juvenile Dermatomyositis	CYCLOSPORINE, METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00035958	Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis	Phase 2/3	75		Dermatomyositis	ETANERCEPT, METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT05524311	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)	Phase 2	16		Juvenile Dermatomyositis	BARICITINIB	Its record names the disease	ClinicalTrials.gov
NCT00004357	Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase 2	6		Vasculitis, Hypersensitivity, Connective Tissue Diseases, Dermatomyositis, Vasculitis	METHYLPREDNISOLONE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT07012057	Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis	Phase 2	0		Myositis, Dermatomyositis	DEUCRAVACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01724580	Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes				Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)	BARICITINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection	0 of 1	0 of 1	2	NCT05000216	Trial comparisons
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine	0 of 1	0 of 1	2	NCT05000216	Trial comparisons
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs)	0 of 1	0 of 1	2	NCT05000216	Trial comparisons
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Medically Attended Adverse Events (MAAEs)	0 of 1	0 of 1	2	NCT05000216	Trial comparisons
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Serious Adverse Events (SAEs)	0 of 1	0 of 1	2	NCT05000216	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41289027	DERIVED	1	PubMed
35786528	DERIVED	1	PubMed
32843325	DERIVED	1	PubMed
29649002	DERIVED	1	PubMed
29134648	DERIVED	1	PubMed
27353819	DERIVED	1	PubMed
27353816	DERIVED	1	PubMed
26645190	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008054

GET https://conductscience.org/api/diseases/v1/MONDO_0008054/drugs

API reference For AI assistants